Dena Howard

Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease

Talha Munir, David A. Cairns, Adrian Bloor et al. · New England Journal of Medicine · 2023 · 155 citations · Full text

Medicine, Oncology, Pharmacotherapy +12

Ibrutinib and rituximab versus fludarabine, cyclophosphamide, and rituximab for patients with previously untreated chronic lymphocytic leukaemia (FLAIR): interim analysis of a multicentre, open-label, randomised, phase 3 trial

Peter Hillmen, Alexandra Pitchford, Adrian Bloor et al. · The Lancet Oncology · 2023 · 106 citations · Full text

Medicine, Immunology, Pharmacotherapy +14

Whole-genome sequencing of chronic lymphocytic leukemia identifies subgroups with distinct biological and clinical features

Pauline Robbe, Kate Ridout, Dimitrios V. Vavoulis et al. · Nature Genetics · 2022 · 78 citations · Full text

Life Sciences, Genetics, Oncology +17

Recommendations on multiple testing adjustment in multi-arm trials with a shared control group

Dena Howard, Julia Brown, Susan Todd et al. · Statistical Methods in Medical Research · 2016 · 62 citations · Full text

Public Health, Biostatistics, Comparative Effectiveness Research +16

Ibrutinib Plus Rituximab Is Superior to FCR in Previously Untreated CLL: Results of the Phase III NCRI FLAIR Trial

Peter Hillmen, Alexandra Pitchford, Adrian Bloor et al. · Blood · 2021 · 36 citations

Medicine, Pharmacology, Pharmacotherapy +5